{"id":8348,"date":"2026-04-20T14:14:16","date_gmt":"2026-04-20T14:14:16","guid":{"rendered":"https:\/\/www.europesays.com\/ai\/8348\/"},"modified":"2026-04-20T14:14:16","modified_gmt":"2026-04-20T14:14:16","slug":"viewsml-raises-4-9-million-for-ai-based-virtual-tissue-staining","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ai\/8348\/","title":{"rendered":"ViewsML Raises $4.9 Million for AI-Based Virtual Tissue Staining"},"content":{"rendered":"

ViewsML<\/a>, a company developing software for tissue analysis<\/a>, announced the completion of an oversubscribed $4.9 million seed funding round led by Wittington Ventures. New investors Continuum Health Ventures and Mayo Clinic<\/a> also participated, alongside repeat investors RiSC Capital, Debiopharm, WUTIF, Defined, and e-Fund.<\/p>\n

The capital will be used to accelerate the commercialization of the company\u2019s artificial intelligence<\/a>-driven virtual biomarker staining platform. The company also plans to expand strategic partnerships, advance clinical validation of virtual biomarker panels, and grow its engineering, scientific, and commercial teams.<\/p>\n

Virtual Staining Technology<\/p>\n

The platform uses AI to generate per-cell biomarker spatial insights from pathology images<\/a> without the need for traditional laboratory staining. As demand for high-resolution biomarker data increases in drug development and diagnostics, traditional staining workflows have become a bottleneck, according to the company.<\/p>\n

The technology produces spatial biomarker insights from standard hematoxylin and eosin slides. This approach preserves scarce tissue samples while accelerating research, clinical trials, and patient care, according to a press release from the company.<\/p>\n

\u201cBiomarkers<\/a> are foundational to how we understand and treat disease, yet the way we measure them remains constrained by legacy approaches. ViewsML is redefining how biomarkers are measured and analyzed, unlocking a step-change in speed, scale, and accessibility across research and clinical settings,\u201d says Zeeshan Ali, partner, Wittington Ventures, in a release.<\/p>\n

Accelerating Immunohistochemistry Workflows<\/p>\n

By building a virtual biomarker library, the company aims to convert a traditionally lab-bound process into software. This shift enables an entirely new paradigm for assay development, according to the company.<\/p>\n

\u201cWe\u2019re building the computational layer for next-generation diagnostics, and are excited to partner with Wittington Ventures and work with Mayo Clinic to accelerate that vision,\u201d says Kenneth To, ceo, ViewsML, in a release. \u201cThis capital will enable us to fast-track our efforts to revolutionize immunohistochemistry. By building the world\u2019s first virtual biomarker library, we\u2019re going to empower scientists and clinicians to analyze biomarker staining in minutes rather than the traditional days or weeks.\u201d<\/p>\n

ViewsML is presenting several poster sessions with partners at the American Association for Cancer Research Annual Meeting<\/a> 2026, held in San Diego from April 17-22.<\/p>\n

ID 429582737<\/a> \u00a9 Yuri Arcurs<\/a> | Dreamstime.com<\/a><\/p>\n

Related Reading:<\/p>\n

\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"ViewsML, a company developing software for tissue analysis, announced the completion of an oversubscribed $4.9 million seed funding…\n","protected":false},"author":2,"featured_media":8349,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[24,25,7285,7286,7287,1720,6238,7288,7289,7290,4478,7291,7292],"class_list":{"0":"post-8348","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ai","8":"tag-ai","9":"tag-artificial-intelligence","10":"tag-biomarkers","11":"tag-clinical-diagnostics","12":"tag-digital-pathology","13":"tag-drug-development","14":"tag-healthcare-technology","15":"tag-immunohistochemistry","16":"tag-laboratory-automation","17":"tag-pathology","18":"tag-seed-funding","19":"tag-tissue-analysis","20":"tag-virtual-staining"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/8348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/comments?post=8348"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/8348\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media\/8349"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media?parent=8348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/categories?post=8348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/tags?post=8348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}